LIGAND PHARMACEUTICALS INCORPORATED Finite-Lived Intangible Asset, Expected Amortization, Year Three
LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) had Finite-Lived Intangible Asset, Expected Amortization, Year Three of $31.66 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree · last filed 2026-02-27
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $31.66M.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $32.70M.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $32.80M.
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $34.10M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Three |
|---|---|
| 2025-12-31 | $31.66M 10-K · filed 2026-02-27 |
| 2024-12-31 | $32.70M 10-K · filed 2025-02-28 |
| 2023-12-31 | $32.80M 10-K · filed 2024-02-29 |
| 2022-12-31 | $34.10M 10-K · filed 2023-02-28 |
| 2021-12-31 | $47.00M 10-K · filed 2022-02-28 |
| 2020-12-31 | $47.10M 10-K · filed 2021-02-24 |
| 2019-12-31 | $14.10M 10-K · filed 2020-02-27 |
| 2018-12-31 | $12.80M 10-K · filed 2019-02-28 |
| 2017-12-31 | $12.80M 10-K · filed 2018-03-01 |
| 2016-12-31 | $10.60M 10-K · filed 2017-02-28 |
| 2016-03-31 | $10.70M 10-Q · filed 2016-11-14 |
| 2015-12-31 | $2.40M 10-K · filed 2016-11-14 |
| 2015-09-30 | $2.40M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $2.40M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $2.40M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $2.40M 10-K · filed 2015-02-23 |
| 2014-09-30 | $2.40M 10-Q · filed 2014-10-31 |
| 2014-06-30 | $2.40M 10-Q · filed 2014-08-05 |
| 2014-03-31 | $2.40M 10-Q · filed 2014-05-07 |
| 2013-12-31 | $2.40M 10-K/A · filed 2014-12-12 |
| 2013-09-30 | $2.40M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $2.40M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $2.40M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $2.40M 10-K · filed 2013-03-14 |
| 2012-09-30 | $2.30M 10-Q · filed 2012-11-14 |